A New Standard for Copay Excellence: Q&A with Brian Laird

Key Takeaways

• EVERSANA runs 80+ copay programs, 12M claims, 1.5M patients.
• Intelligent Copay uses AI to detect fraud and route claims dynamically.
• New solution gives manufacturers real‑time spend visibility and risk protection.
• Traditional single‑vendor models lack flexibility for high‑deductible plans.
• Future copay programs will be adaptive, patient‑centric, and data‑driven.

Pulse Analysis

Rising drug prices and the proliferation of high‑deductible health plans have turned copay assistance from a simple rebate into a strategic lever for pharmaceutical firms. Payers now employ accumulators, maximizers and variable formulary designs that can abruptly cut patient access, forcing manufacturers to seek more granular control over how assistance dollars are allocated. In this environment, traditional single‑vendor, static adjudication models struggle to keep pace, creating gaps that jeopardize both patient continuity and the financial integrity of affordability programs.

EVERSANA’s Intelligent Copay Solution answers that gap by embedding artificial intelligence and a flexible data architecture into the core of copay management. AI algorithms continuously scan claim patterns to flag potential fraud, waste or abuse before they scale, while real‑time routing directs each transaction through the most cost‑effective adjudication pathway. This dynamic approach not only curtails leakage but also furnishes manufacturers with dashboards that detail spend, utilization trends and optimization opportunities, turning a once‑transactional service into a proactive financial instrument.

Looking ahead, the copay landscape will evolve toward fully adaptive, patient‑centric ecosystems where transparency, speed and predictive analytics are non‑negotiable. Programs will need to integrate seamlessly with broader commercialization efforts, linking adherence data, patient engagement tools and market access strategies. Companies that adopt intelligent, data‑driven copay platforms now will be better positioned to maintain therapy continuity, meet regulatory scrutiny and sustain profitability as the market’s complexity deepens.